Polyclonal Antibody to Akt (Phospho-Thr308)
Figure 1: Western blot analysis of extracts from Hela cells untreated or treated with EGF, serum or both using Akt(Phospho-Thr308) Antibody 35-1054 .
Roll over image to zoom in
Shipping Info:
For estimated delivery dates, please contact us at [email protected]
| Format : | Purified |
| Amount : | 100 µl |
| Isotype : | Rabbit IgG |
| Content : | Supplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. |
| Storage condition : | Store the antibody at 4°C, stable for 6 months. For long-term storage, store at -20°C. Avoid repeated freeze and thaw cycles. |
General protein kinase capable of phosphorylating several known proteins. Phosphorylates TBC1D4. Signals downstream of phosphatidylinositol 3-kinase (PI3K) to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor I (IGF-I). Plays a role in glucose transport by mediating insulin-induced translocation of the GLUT4 glucose transporter to the cell surface. Mediates the antiapoptotic effects of IGF-I. Mediates insulin-stimulated protein synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby activating mTORC1 signaling and leading to both phosphorylation of 4E-BP1 and in activation of RPS6KB1. Promotes glycogen synthesis by mediating the insulin-induced activation of glycogen synthase. Tremblay F, et al. (2005)Diabetes; 54(9): 2674-84. Xu BE, et al. (2005)J Biol Chem; 280(40): 34218-23. Samuels Y, et al. (2005)Cancer Cell; 7(6): 561-73. Di Maira G, et al. (2005)Cell Death Differ; 12(6): 668-77.
Predicted MW: 60kd, Western blotting: 1:500~1:1000, Immunohistochemistry: 1:50~1:100, Immunofluorescence: 1:100~1:200
For Research Use Only. Not for use in diagnostic/therapeutics procedures.
| Subcellular location: | Cytoplasm, Nucleus, Cell membrane |
| Post transnational modification: | Acetylated on Lys-14 and Lys-20 by the histone acetyltransferases EP300 and KAT2B. Acetylation results in reduced phosphorylation and inhibition of activity. Deacetylated at Lys-14 and Lys-20 by SIRT1. SIRT1-mediated deacetylation relieves the inhibition. |
| Tissue Specificity: | Expressed in prostate cancer and levels increase from the normal to the malignant state (at protein level). Expressed in all human cell types so far analyzed. The Tyr-176 phosphorylated form shows a significant increase in expression in breast cancers during the progressive stages i.e. normal to hyperplasia (ADH), ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC) and lymph node metastatic (LNMM) stages. |
| BioGrid: | 106710. 302 interactions. |
|
There are currently no product reviews
|
.png "ACE2/HEK293 Stable Cell Line")
